Elucid Bioimaging Inc. (“Elucid”) today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products.
Elucid is aware of a lawsuit filed by Heartflow, Inc., on October 22, 2026. Elucid will respond to and defend against the claims in the lawsuit through the appropriate legal channels.
“Elucid was founded to help physicians predict cardiovascular risk and personalize prevention for each patient, so that more heart attacks and strokes can be avoided,” said Kelly Huang, PhD, CEO of Elucid. “We fully believe in the uniqueness of our products and technology, we are confident in their independent development, and we have invested substantially for over a decade in building a robust intellectual property portfolio. Our commitment to patients and physicians is unchanged, and we remain focused on supporting the clinicians and care teams who seek better solutions for patient care.”
That commitment is reflected in Elucid’s technology. Elucid, an innovator of AI-powered cardiovascular imaging software, seeks to advance the standard of care by bringing FFR-IQ™ and Plaque-IQ™ together in a comprehensive clinical platform that integrates coronary anatomy, physiology and plaque biology from a single CCTA, supported by a new interface and reporting workflow. This integration supports lesion-specific assessment and personalized medical and interventional decisions.
About Elucid
Elucid is a Boston-based medical technology company developing AI that sees beyond what the human eye can see in coronary and carotid CT angiography scans, supporting a path for personalized therapy to prevent heart attack and stroke. The company is dedicated to advancing CCTA-guided personalized cardiovascular care by providing physicians with a more precise view of atherosclerosis, the root cause of cardiovascular disease. Elucid’s FDA-cleared Plaque-IQ™ image analysis software objectively quantifies and characterizes atherosclerotic plaque and has the ability to detect Lipid Rich Plaque with high accuracy, providing physicians with information about the amount and type of plaque present in the coronary and carotid arteries. Its newly FDA-cleared FFR-IQ™ software provides noninvasive assessment of coronary physiology (FFR-CT) derived from Elucid’s plaque analysis, integrating anatomy, plaque biology, and physiology to help physicians identify coronary blockages, the degree of coronary stenosis, and the quantitative extent of a patient’s ischemia. Together, Elucid’s technologies are designed to help physicians move beyond population-based risk and anatomical assessment toward a more comprehensive, personalized understanding of each patient’s actual disease.
For more information, visit www.elucid.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261023017990/en/